We are pleased to announce that the Think Rare Program — EIP's dedicated educational initiative for rare diseases in children— is growing once again.
Since its launch, the Think Rare program has been equipping pediatricians and general practitioners worldwide with the knowledge they need to recognize and act on rare conditions early — because early recognition can change everything in rare diseases. Building on our established Learning Zones for Mucopolysaccharidoses (MPS), Metachromatic Leukodystrophy (MLD), and Alpha-Mannosidosis (AM), Think Rare now expands to cover CLN2 (Neuronal Ceroid Lipofuscinosis Type 2), more commonly known as Batten disease.
CLN2 is a rare, progressive, and devastating neurodegenerative disorder affecting young children. Early manifestations can vary and be subtle, and because they can overlap with more common pediatric conditions, CLN2 is often unrecognized for too long. Despite the availability of an approved enzyme replacement therapy, the condition remains severely underdiagnosed, and delays in recognition can have profound consequences for affected children and their families.
This is precisely why Think Rare is expanding here. By helping frontline clinicians recognize the early warning signs of CLN2 and understand the diagnostic pathway, we can shorten the often lengthy journey to diagnosis and connect families with the care they need sooner.
As part of this new segment, we will organize 4 live educational webinars in the second semester of 2026, bringing together leading experts in pediatric neurology and metabolic diseases. The webinars will cover early recognition, differential diagnosis, the diagnostic journey, available treatments, and multidisciplinary care for children living with CLN2.
Exact dates and registration links will be announced shortly — stay tuned.
Think Rare. Act Early. Transform Lives.
